体外生命支持治疗急性大面积肺栓塞的结局:一项系统评价
该系统评价纳入50项病例系列或病例报告,共128例需要ECLS的急性大面积肺栓塞患者,提取患者层面数据进行统计分析。中位年龄50岁,67.2%(86/128)表现为心脏骤停,97.1%(99/102)使用静脉-动脉ECLS,中位ECLS时间3天。85.1%(97/114)成功脱离ECLS,30天死亡率为22%(20/91),死亡最常见原因为休克(30.3%,10/33)。作者结论认为ECLS在急性大面积肺栓塞不稳定患者中是安全有效的治疗,结局可接受。
要点
- 128例急性大面积肺栓塞需ECLS患者中,67.2%(86/128)表现为心脏骤停,30天死亡率为22%(20/91)。
- ECLS模式以静脉-动脉ECLS为主(97.1%,99/102),中位ECLS时间3天,85.1%(97/114)成功脱离ECLS。
- 43.0%(55/128)接受全身溶栓,22.7%(29/128)接受导管导向溶栓,37.5%(48/128)接受外科取栓。
- ECLS后出血并发症为23.4%(30/128),急性肾衰竭8.6%(11/128),透析6.3%(8/128)。
- 死亡最常见原因为休克(30.3%,10/33),中位住院时间22天,其中ICU 8天。
适用人群与场景
- 急性大面积肺栓塞导致血流动力学不稳定、需要ECLS的患者,来自50项病例系列或病例报告,共128例。
- 中位年龄50岁(范围36-63岁),男性占41.3%(50/121)。
处置流程与药物剂量
- ECLS模式:静脉-动脉ECLS占97.1%(99/102),中位ECLS时间3天(范围2-6天)。
- 确定性治疗包括全身溶栓43.0%(55/128)、导管导向溶栓22.7%(29/128)、外科取栓37.5%(48/128)。
红旗征与不能漏的情况
- 心脏骤停:67.2%(86/128)的患者表现为心脏骤停。
- 休克为最常见死亡原因,占30.3%(10/33)。
研究设计与关键结果
- 系统评价纳入50项病例系列或病例报告,共128例急性大面积肺栓塞需ECLS的患者,提取患者层面数据。
- 中位心率126次/分(范围118-135),中位收缩期肺动脉压55 mmHg(范围48-69)。
- 85.1%(97/114)成功脱离ECLS。
- ECLS后并发症:出血23.4%(30/128),急性肾衰竭8.6%(11/128),透析6.3%(8/128),肝素诱导的血小板减少症3.1%(4/128),肢体低灌注2.3%(3/128)。
- 30天死亡率为22%(20/91);中位住院时间22天(范围11-39),其中ICU 8天(范围5-13)。
证据类型、等级与局限
- 证据类型:系统评价,纳入50项病例系列或病例报告,共128例患者。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,ECLS在急性大面积肺栓塞不稳定患者中是安全有效的治疗,结局可接受。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Massive pulmonary embolism (PE) can cause hemodynamic instability leading to high mortality. Extracorporeal life support (ECLS) has been increasingly used as a bridge to definitive therapy. This systematic review investigates the outcomes of ECLS for the treatment of massive PE.
METHODS: Electronic search was performed to identify all relevant studies published on ECLS use in patients with PE. 50 case series or reports were selected comprising 128 patients with acute massive PE who required ECLS. Patient-level data were extracted for statistical analysis.
RESULTS: Median patient age was 50 [36, 63] years and 41.3% (50/121) were male. 67.2% (86/128) of patients presented with cardiac arrest. Median heart rate was 126 [118, 135] and median systolic pulmonary artery pressure (sPAP) was 55 [48, 69] mmHg. The majority of ECLS included veno-arterial ECLS [97.1% (99/102)]. Median ECLS time was 3 [2, 6] days. 43.0% (55/128) patients received systemic thrombolysis, 22.7% (29/128), received catheter-guided thrombolysis, and 37.5% (48/128) underwent surgical embolectomy. 85.1% (97/114) were weaned off ECLS. Post-ECLS complications included bleeding in 23.4% (30/128), acute renal failure in 8.6% (11/128), dialysis in 6.3% (8/128), heparin-induced thrombocytopenia in 3.1 (4/128), and extremity hypoperfusion in 2.3% (3/128). The most common cause of death was shock at 30.3% (10/33). The median length of hospital stay was 22 [11, 39] days including 8 [5, 13] intensive care unit (ICU) days. The 30-day mortality rate was 22% (20/91).
CONCLUSIONS: ECLS is safe and effective therapy in unstable patients with acute massive pulmonary embolism and offers acceptable outcomes.
参考来源
- O'Malley TJ, Choi JH, Maynes EJ, et al. Outcomes of extracorporeal life support for the treatment of acute massive pulmonary embolism: A systematic review. Resuscitation. 2019. PMID: 31790756. doi:10.1016/j.resuscitation.2019.11.018
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。